Table: Kyowa Kirin -2023 group results (IFRS)
Feb 7 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2023 Dec 31, 2022 Dec 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 442.23 398.37 473.00
(+11.0 pct) (+13.1 pct) (+7.0 pct)
Operating
Pretax 97.25 67.57 85.00
(+43.9 pct) (+12.5 pct) (-12.6 pct)
Net 81.19 53.57 63.00
(+51.5 pct) (+2.3 pct) (-22.4 pct)
EPS Basic 151.03 yen 99.68 yen 119.07 yen
EPS Diluted 151.01 yen 99.66 yen
Ann Div 56.00 yen 51.00 yen 58.00 yen
-Q2 Div 27.00 yen 24.00 yen 29.00 yen
-Q4 Div 29.00 yen 27.00 yen 29.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia